4-(环辛基)吡啶-3-磺酰胺 | 76287-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(环辛基)吡啶-3-磺酰胺
• 英文名称: 4-(cyclooctylamino)pyridine-3-sulfonamide
• 英文别名: 4-cyclooctylylaminopyrid-3-ylsulfonamide；(4-(cyclooctylamino)pyrid-3-yl)sulfonamide；4-cyclooctylaminopyridine-3-sulfonamide
• CAS: 76287-10-0
• 化学式: C₁₃H₂₁N₃O₂S
• 分子量: 283.395
• InChiKey: GDFSJCBENRQYAV-UHFFFAOYSA-N

物化性质

• 沸点：
  501.6±60.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  93.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(环辛基)吡啶-3-磺酰胺 在 吡啶 作用下， 以 甲苯 为溶剂， 反应 5.33h， 生成 BM 10
  参考文献：
  名称：

  Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2C1− K+ cotransporter inhibitors

  摘要：

  The pharmacology of lipophilic 4-arylamino- and 4-cycloalkylaminopyrid-3-ylsulfonyl(thio)ureas and their synthesis designed from torasemide are described. These compounds could lead to a method of inhibiting the astrocytic Na+ 2Cl(-) K+ cotransporter and thus treating cerebral edema. Their lipophilicity and ionization constants were determined. Seven lipophilic compounds (17, 18, 22, 23, 24, 32 and 36) exhibited a high inhibitory potency (IC50 < 10 mu M) and had lost the diuretic properties of torasemide. One of them, N-([4-(cycloheptylamino)pyrid-3-yl]sulfonyl)-N'-cycloheptylurea 17 (0.1-1 mg/kg) was found to increase the gasp delay in hypoxia-exposed mice. In preliminary experiments, 17 (1-2.5 mg/kg) strongly reduced the morbidity and mortality rate of gerbils after permanent left carotid artery ligation. In-vitro experiments confirmed its antiedematous activity.

  DOI：

  10.1016/0223-5234(94)90145-7
• 作为产物：
  描述：

  环辛胺 、 4-氯吡啶-3-磺酰胺 生成 4-(环辛基)吡啶-3-磺酰胺
  参考文献：
  名称：

  DeLarge; Lapiere; De Ridder, European Journal of Medicinal Chemistry, 1980, vol. 15, # 4, p. 299 - 304

  摘要：

  DOI：

文献信息

• Pyridothiadiazines
  申请人：Adir et Compagnie

  公开号：US05459138A1

  公开（公告）日：1995-10-17

  The invention relates to a compound selected from those of formula (I): ##STR1## in which A, R.sub.1, R.sub.2 and R.sub.4 are as defined in the description, and medicinal products containing the same which is useful for treating a pathology related to dysfunctioning of glutamatergic neurotransmission.

  该发明涉及一种选择自式(I)的化合物：##STR1##其中A、R.sub.1、R.sub.2和R.sub.4如描述中所定义，并且包含该化合物的药物产品，用于治疗与谷氨酸能神经传递功能障碍相关的病理。
• A Sulphonylthiourea (BM 20) Related to Torasemide: a new Loop Diuretic with Relative Potassium-sparing Properties
  作者：B Masereel、M Schynts、J M Krzesinski、B Pirotte、G Rorive、J Delarge

  DOI：10.1111/j.2042-7158.1993.tb07096.x

  日期：2011.4.12

  A series of sulphonylthioureas related to torasemide, a high ceiling loop diuretic, were synthesized and found to inhibit the Na+ 2Cl− K+ co-transporter of the thick ascending limb of the loop of Henlé. Their diuretic properties were studied (30 mg kg−1) after oral administration to rats. Lipophilic derivatives, very active in-vitro, were found inactive orally and intraperitoneally in rats. The four most active compounds were examined for their dose-dependent diuresis. Three of them showed a potency, water and electrolyte excretion similar to torasemide. The fourth molecule, a sulphonylthiourea (BM 20), exhibited relative potassium-sparing properties and a minimal diuretic dose of 0·001 mg kg−1, 200 times lower than torasemide.

  摘要：合成了一系列与托拉塞米德相关的磺胺基硫脲类化合物，发现它们能抑制肾曲线上皮厚升支部位的Na+ 2Cl− K+协同转运蛋白。这些化合物在口服给大鼠后（30毫克/千克）进行了利尿特性研究。脂溶性衍生物在体外表现出很高的活性，但在大鼠口服和腹腔注射后无活性。对四种最活性化合物进行了剂量依赖性利尿研究。其中三种显示出与托拉塞米德相似的效力，水和电解质排泄。第四种分子，一种磺胺基硫脲（BM 20），表现出相对保钾性质，最小利尿剂剂量为0.001毫克/千克，比托拉塞米德低200倍。
• Design, Synthesis and Biological Activity of a Series of Torasemide Derivatives, Potent Blockers of the Na+ 2Cl− K+ Co-transporter: In-vitro Study
  作者：B Masereel、E Lohrmann、M Schynts、B Pirotte、R Greger、J Delarg

  DOI：10.1111/j.2042-7158.1992.tb05470.x

  日期：2011.4.12

  Pharmacomodulation of the torasemide molecule, a loop diuretic inhibiting Na+ 2Cl− K+ co-transport in the thick ascending limb of the loop of Henlé has been performed in order to obtain new long-acting diuretics. The aim of this study was to decrease the metabolism of the drug and to slow down its rate of excretion by increasing its hydrophobicity. The present study describes the synthesis and the inhibitory potency of new torasemide derivatives in the bioassay system of the cortical thick ascending limb of rabbit. A correlation between the lipophilicity (log P') of these substances and their activity as inhibitors of the Na+ Cl− K+ co-transporter was observed. The present design led to compounds more active than torasemide. Structure-activity relationships permit us to propose an interaction model between torasemide derivatives and the Na+ 2Cl− K+ co-transport system of the cortical thick ascending limb.

  摩尔卡西尼酸分子的药物调节，一种抑制髓袢厚壁升支肢上的Na+ 2Cl− K+共转运的环利尿剂已经进行，以获得新的长效利尿剂。本研究旨在通过增加其疏水性来降低药物的代谢并减慢其排泄速率。本研究描述了新摩尔卡西尼酸衍生物在兔子皮质厚壁升支肢生物测定系统中的合成和抑制效力。观察到这些物质的亲脂性（log P'）与它们作为Na+ Cl− K+共转运抑制剂的活性之间的相关性。目前的设计导致比摩尔卡西尼酸更活跃的化合物。结构活性关系使我们能够提出摩尔卡西尼酸衍生物与皮质厚壁升支肢的Na+ 2Cl− K+共转运系统之间的相互作用模型。
• Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
  申请人：Adir et Compagnie

  公开号：US05166162A1

  公开（公告）日：1992-11-24

  The invention concerns a compound of formula (I) ##STR1## in which: R represents cycloalkyl, bicycloalkyl or polycycloalkyl, X represents oxygen or sulfur, and R1 represents alkyl, cycloalkyl, bicycloalkyl, or polycycloalkyl. Medicaments thereof and use of same is useful in treating a circulatory ailment related to arterial hypertension or peripheral or cerebral oedema.

  该发明涉及一种化合物，其化学式为（I）##STR1##其中：R代表环烷基、双环烷基或多环烷基，X代表氧或硫，R1代表烷基、环烷基、双环烷基或多环烷基。该化合物及其药物在治疗与动脉高压或外周或脑水肿相关的循环疾病方面具有用途。
• Nouvelles pyridothiadiazines, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：ADIR ET COMPAGNIE

  公开号：EP0618209A1

  公开（公告）日：1994-10-05

  L'invention concerne les composés de formule (I) : dans laquelle A, R₁, R₂, et R₄ sont tels que définis dans la description. Médicaments.

  本发明涉及式 (I) 化合物： 其中 A、R₁、R₂ 和 R₄ 如描述中所定义。 药物。